You’ll also want to avoid harsher cleansers, which “can strip the necessary lipids and proteins that make up the brick-and-mortar structure of a healthy skin barrier,” Waldorf advises.

BioAge valued at $758 mln in debut as investors bet on weight-loss drug frenzy September 26, 2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead ...

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic ...

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases ...

Leaving no stone unturned, this mini kit offers hydration in the form of a serum, a lightweight mask, a cleanser, and a mini lip balm. An ELLE editor says: “My favorite Summer Friday staples are ...

On Monday, Morgan Stanley (NYSE:MS) initiated coverage on BioAge Labs Inc (NASDAQ:BIOA), assigning the stock an Overweight rating and setting a price target of $40.00. The new rating reflects the ...

On Monday, Citi initiated coverage on BioAge Labs Inc (NASDAQ:BIOA) shares, giving the biotech company a Buy rating and setting a price target of $45.00. The firm highlighted BioAge's focus on ...

Goldman Sachs initiated coverage of BioAge Labs (BIOA) with a Not Rated. The firm models for peak azelaprag sales of $8.5B in 2036 via peak penetration of 15% into the incretin-treated market.